ISRCTN10903007
Completed
未知
Treatment of benign bone lesions with an injectable biphasic bone substitute
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Benign bone lesions
- Sponsor
- Medical University of Vienna
- Enrollment
- 18
- Status
- Completed
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients who:
- •1\. Received treatment with a ceramic biphasic bone substitute
- •2\. For benign bone tumors and tumor\-like lesions
- •3\. With a complete set of retrospective information, including surgical protocols, X\-rays, patient dismission letters and outpatient clinic protocols
- •4\. With a minimum follow\-up of 1 year after surgery
Exclusion Criteria
- •1\. Inconclusive data with missing surgical or histological reports
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
A new method for the treatment of intractable bony ankylosis of the temporomandibular joint utilizing intentional pseudoarthrosisbony ankylosis of the temporomandibular jointJPRN-UMIN000041958Kyorin University School of Medicine4
Not yet recruiting
Phase 3
role of injectable platelet rich fibrin in periodontal diseasesCTRI/2023/09/057296TEPARAMESWARI
Recruiting
Not Applicable
ew Therapies for bone and cartilage defects using bone marrownot applicable1002321310046304NL-OMON43408Orthopaedie200
Recruiting
Phase 3
A clinical trial to study the effects of mumps-measles-rubella vaccine in improving patients with multiple warts in skiHealth Condition 1: null- Multiple Cutaneous WartsCTRI/2017/10/010021Dr Prof Shyam Sundar Chaudhary
Completed
Phase 1
InCCNM -ISkin basal cell carcinoma, Squamous cells carcinoma.Carcinoma, Basal CellSkin NeoplasmsCarcinoma, Squamous CellNeoplasms, Basal CellNeoplasms, Glandular and EpithelialNeoplasms, Squamous CellCarcinomaSkin DiseasesRPCEC00000052Center for Genetic Engineering and Biotechnology (CIGB)21